UBS Flags Midcap Valuation Risk, Favors Five Sectors
Overview
UBS analysts note Indian midcap valuations remain near five-year averages despite a modest correction in 2025, raising concerns about limited downside. While domestic fund inflows have supported Small and Mid-Cap stocks (SMIDs), a pivot by fund managers to large caps could pressure performance. UBS recommends a bottom-up approach, highlighting five sectors with attractive valuations.
Stocks Mentioned
Midcap Valuations Show Little Room for Further Decline
Swiss bank UBS has assessed India's midcap market, finding that despite underperformance in 2025, valuations have only seen a marginal correction. The midcap index's one-year-forward Price-to-Earnings (PE) ratio declined approximately 10% for the year. However, this valuation remains at a premium compared to its five-year average and the benchmark Nifty index.
Fund Flow Support and Potential Reversal Risks
Domestic fund flows have been a critical pillar for Small and Mid-cap stocks (SMIDs) throughout 2025, with cumulative inflows up 37% year-on-year. Focused mid-cap and small-cap funds saw inflows rise by 46% and 53%, respectively. UBS expresses concern that a reversal in these flows could significantly impact SMID performance, especially as domestic fund managers appear to be shifting towards large-cap stocks.
UBS's Sector-Specific Investment Strategy
UBS advocates for a bottom-up, sector-specific investment approach within the midcap space. The brokerage analyzed 20 segments predominantly comprising SMIDs. Most of these segments are currently trading close to their five-year average valuation multiples, though a few, including hospitals, cables, and capital markets, are trading at premiums.
Key Sectors in Focus
Home Improvement and Pipes: This segment trades at a 15% discount to its long-term average, influenced by soft demand. Tile and ceramic companies face a roughly 25% discount, while plywood firms trade near historical levels.
Hospitality: Listed hospitality stocks are trading about 15% below their five-year average. Despite concerns about a potential cycle peak, demand, particularly in the luxury segment, continues to outstrip supply.
Diagnostics: Valuations are hovering near long-term averages, but company-specific performance varies. Market leader Dr Lal PathLabs, for instance, is trading at a discount of around 20% to its historical average.
Chemicals: The chemical sector's valuations are broadly aligned with long-term averages. However, individual company outcomes differ significantly, with some experiencing de-ratings due to pricing pressures.
Capital Markets: This segment trades slightly above its long-term average, buoyed by strong operating performance from exchanges like Multi Commodity Exchange (MCX) and BSE, which have seen re-ratings driven by volume growth.
Midcap Re-rating Trend Reversed
In contrast to a consistent re-rating trend in the two years following 2022, the midcap segment experienced a de-rating of 11% in 2025. This contrasts with the Nifty, which saw a 7% re-rating over the same period, signaling a relative cooling in midcap valuations.
